BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026?
BrightSpring's shares surge 67.3% year to date, fueled by strong pharmacy and provider growth, improving profitability and a brighter 2026 outlook.
BTSG - BrightSpring Health Services, Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$77.50
DETAILS
HIGH:
$90.00
LOW:
$64.00
MEDIAN:
$80.00
CONSENSUS:
$77.50
UPSIDE:
27.32%
Stock News
BrightSpring: Margins Keep Improving While Expanding Its Pharmacy Footprint
I believe BrightSpring Health Services' pharmacy and home-care businesses have a few ways to monetize their sizeable revenues into higher EBITDA over time. BTSG's new oncology distribution wins also grow their addressable market, which is why drug adoption is vital going forward. BTSG's recently acquired home-health branches also have interesting potential as their integration progresses.
Top Healthcare Stocks: Playing Offense And Defense For The Win
Healthcare offers investors a potential combination of offense with forward earnings and defense with rising demand amid persistent macro-economic uncertainty. The healthcare sector is positioned for above-average long-term growth, supported by aging demographics, rising medical demand, and increased spending that's expected to outpace the broader economy. Strong forward revenue, EBITDA, and earnings growth demonstrate how select healthcare services and facilities companies can significantly outperform their sector peers.
BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026
LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 financial results on Friday, October 30, 2026, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day.
BTSG Deploys AI Across Operations: Will It Improve Margins?
BrightSpring Health Services is expanding AI and automation across its operations, with early margin gains and more benefits expected later in 2026 and 2027.
BrightSpring Health Services, Inc. (BTSG) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BrightSpring vs. Option Care Health: Which Healthcare Stock Is Better?
BrightSpring's faster growth, pharmacy and provider-service expansion, and improving margins contrast with OPCH's slower growth and chronic-therapy pressures.
BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI
BrightSpring Health Services (NASDAQ: BTSG) outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for complex patients. Chief Financial Officer Jen Phipps described BrightSpring as a home- and community-based provider serving specialty and senior populations. The
BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI
BrightSpring Health Services NASDAQ: BTSG outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for complex patients.
Will M&A Be the Next Growth Factor as BTSG's Cash Flow and Leverage Improve?
BTSG's stronger cash flow and lower leverage could give it more flexibility to pursue acquisitions and support future growth.
Best Momentum Stocks to Buy for September 24th
RDVT, BTSG and THC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 24th, 2026.
3 Momentum Anomaly Stocks to Buy as Markets Surge on AI Rally
Centene, BrightSpring and Delek combine 52-week gains with short-term pullbacks, putting them in focus as momentum plays for volatile markets.
BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability
BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore
BrightSpring Health Services is rated buy, driven by rapid profitability growth, expanding Provider Services, and reduced financial leverage. In Q2, revenue grew 23% and adjusted EBITDA surged 44%, with management raising 2026 guidance for both revenue and EBITDA. BTSG's premium 34.38x FY1 P/E is justified by strong EBITDA growth and a forward PEG of 0.73x, with multiples declining to 22.19x by FY3.
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.
NVIDIA & 2 Profitable Stocks to Buy in September for Big Upside
NVDA's 63.7% net profit margin and 93.3% expected earnings growth put it among three profitable stocks positioned for market volatility.
Price Targets
BrightSpring Health price target raised to $70 from $60 at Deutsche Bank
$70.00
(was $60.82)
Deutsche Bank
BrightSpring Health price target raised to $80 from $71 at Morgan Stanley
$80.00
(was $70.00)
Morgan Stanley
BrightSpring Health price target raised to $80 from $60 at KeyBanc
$80.00
(was $69.64)
KeyBanc
BrightSpring Health price target raised to $78 from $61 at Wells Fargo
$78.00
(was $71.43)
Stephen Baxter
·
Wells Fargo
BrightSpring Health initiated with a Buy at Guggenheim
$81.00
(was $71.43)
Guggenheim
BrightSpring Health initiated with an Outperform at Raymond James
$80.00
(was $71.58)
Parker Snure
·
Raymond James
BrightSpring Health price target raised to $85 from $63 at UBS
$85.00
(was $70.44)
UBS
BrightSpring Health price target raised to $90 from $65 at BTIG
$90.00
(was $66.25)
David Larsen
·
BTIG
BrightSpring Health price target raised to $81 from $65 at TD Cowen
$81.00
(was $64.43)
Cowen & Co.
Goldman Sachs Starts BrightSpring Health (BTSG) at Buy
$71.00
(was $57.40)
Scott Fidel
·
Goldman Sachs
BrightSpring Health (BTSG) PT Raised to $71 at Morgan Stanley
$71.00
(was $59.98)
Erin Wright
·
Morgan Stanley
BrightSpring Health price target raised to $70 from $60 at BMO Capital
$70.00
(was $59.16)
BMO Capital
BrightSpring Health price target raised to $62 from $48 at Morgan Stanley
$62.00
(was $52.44)
Morgan Stanley
BrightSpring Health price target raised to $60 from $50 at Deutsche Bank
$60.00
(was $53.51)
Deutsche Bank
BrightSpring Health price target raised to $65 from $55 at BTIG
$65.00
(was $52.58)
BTIG
BrightSpring Health price target raised to $64 from $53 at Stephens
$64.00
(was $52.58)
Stephens
BrightSpring Health price target raised to $60 from $55 at KeyBanc
$60.00
(was $52.58)
KeyBanc
BrightSpring Health price target raised to $61 from $50 at Wells Fargo
$61.00
(was $52.58)
Stephen Baxter
·
Wells Fargo
BrightSpring Health price target raised to $60 from $52 at BMO Capital
$60.00
(was $52.58)
BMO Capital
Leerink Partners Reiterates Outperform on BrightSpring Health (BTSG) after Investor Day
$49.00
(was $43.82)
Whit Mayo
·
Leerink Partners